Kindred Biosciences to Present at Stifel 2018 Dental & Veterinary Conference

SAN FRANCISCO, May 24, 2018 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the Stifel 2018 Dental & Veterinary Conference on May 30, 2018 in New York City. Denise Bevers, Co-Founder and Chief Operating Officer, will present and be available for one-on-one meetings along […]

Kindred Biosciences Announces First Quarter 2018 Financial Results

San Francisco, CA (May 8, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2018 and provided updates on its programs. “We are excited about the recent approval of our first product, Mirataz™, for […]

Kindred Biosciences Receives FDA Approval of Mirataz™ (mirtazapine transdermal ointment) for the Management of Weight Loss in Cats

San Francisco, CA (May 7, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine approved Mirataz (mirtazapine transdermal ointment) for the management of weight loss in cats. “We are pleased to announce the […]

Kindred Biosciences Announces the Appointment of Dr. Ernest Mario and Dr. Joseph McCracken to its Board of Directors

San Francisco, CA (April 25, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the appointment of Ernest Mario, Ph.D. and Joseph McCracken, D.V.M. to its Board of Directors. Dr. Mario brings to KindredBio 50 years of experience in the pharmaceutical industry. He was […]

Kindred Biosciences Provides Updates on Pending Drug Approvals

San Francisco, CA (April 25, 2018) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has received a response from the Food and Drug Administration (FDA) for the Chemistry, Manufacturing, and Controls technical section for Zimeta IV for the control of fever in […]